At a glance
- Originator Almirall-Prodesfarma
- Class Erectile dysfunction therapies; Small molecules
- Mechanism of Action Type 5 cyclic nucleotide phosphodiesterase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Erectile dysfunction
Most Recent Events
- 23 Mar 2007 Discontinued - Phase-I for Erectile dysfunction in Spain (PO)
- 18 Sep 2002 Phase-I clinical trials in Erectile dysfunction in Spain (PO)